StageZero Life Sciences Ltd. (OTCMKTS:GNWSF) Short Interest Down 18.7% in March

StageZero Life Sciences Ltd. (OTCMKTS:GNWSF) was the recipient of a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 62,500 shares, a drop of 18.7% from the March 15th total of 76,900 shares. Based on an average daily trading volume, of 75,300 shares, the short-interest ratio is currently 0.8 days.

StageZero Life Sciences stock opened at $0.58 on Wednesday. The stock has a market cap of $36.11 million, a price-to-earnings ratio of -2.24 and a beta of 3.02. The company’s 50-day moving average price is $0.88 and its two-hundred day moving average price is $0.72. StageZero Life Sciences has a 52 week low of $0.30 and a 52 week high of $1.27.

Separately, Clarus Securities cut shares of StageZero Life Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 6th.

StageZero Life Sciences Company Profile

StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood.

See Also: Penny Stocks, Risk and Reward Factors

Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.